Lawrence M. Blatt - 09 Mar 2026 Form 4 Insider Report for Aligos Therapeutics, Inc. (ALGS)

Reporting relationship: President and CEO, Director
Issuer ticker: ALGS
Reported as of: 09 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Mar 2026, 16:13:06 UTC
Prior SEC filing: 18 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt

Key filing fact

Lawrence M. Blatt filed Form 4 for Aligos Therapeutics, Inc. (ALGS) on 11 Mar 2026.

Key facts

This page summarizes Lawrence M. Blatt's Form 4 filing for Aligos Therapeutics, Inc. (ALGS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Mar 2026, 16:13.

Change

Previous filing in this sequence was filed on 18 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001242110 Primary reporting owner

BLATT LAWRENCE

Relationship: President and CEO, Director
Address: C/O ALIGOS THERAPEUTICS, INC., 1 CORPORATE DRIVE, 2ND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Lesley Ann Calhoun, as attorney-in fact for Lawrence M. Blatt
Signature date: 11 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALGS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +105,840
Change %
Price: $0.000000^*
Shares after: 105,840
Date: 09 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 105,840
Exercise price: $7.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from March 9, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.